Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
With
Genentech, Inc.
Age
21–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
participants with active RA
completed 24 weeks of treatment in WA16291 or WA17043
eligible for re-treatment, based on clinical symptoms (Disease Activity Score in 28 joints \>=2.6)
females of childbearing potential using reliable contraception
You may not be if
participants who participated in rituximab studies WA16291 or WA17043 but withdrew into the safety follow-up phases of these trials
previous rituximab non-responders
current treatment with any other disease-modifying drug (apart from methotrexate), or any anti-tumor necrosis factor alfa, anti-interleukin-1, or other biologic therapies
participants with known active infection of any kind
evidence of any new or uncontrolled concomitant disease or development of any new contraindications which would preclude repeat treatment with rituximab
history of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies
female participants who are pregnant or breastfeeding
Clareo Health | Extension Study to Assess the Efficacy and Safety of Repeat Treatment With Rituximab (MabThera) in Participants With Active Rheumatoid Arthritis (RA)
